CTP-347

CTP-347 is a deuterated analog of the selective serotonin reuptake inhibitor (SSRI) paroxetine, developed by Concert Pharmaceuticals primarily for the treatment of vasomotor symptoms (hot flashes) associated with menopause. By replacing specific hydrogen atoms with deuterium, the drug was engineered to reduce the mechanism-based inhibition of the cytochrome P450 2D6 (CYP2D6) enzyme, a common issue with standard paroxetine that leads to significant drug-drug interactions and non-linear pharmacokinetics. Although it maintained similar selectivity and potency for serotonin and norepinephrine transporters as its parent compound in preclinical models, development was discontinued following Phase I clinical trials.

Other names

deuterated paroxetineD6-paroxetineD-6-paroxetineD 6-paroxetine